Novo Nordisk As Stock Cash And Equivalents
| NVO Stock | USD 104.56 0.50 0.48% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
Novo | Cash And Equivalents |
Novo Nordisk AS Company Cash And Equivalents Analysis
Novo Nordisk's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Novo Nordisk Cash And Equivalents | 37.47 B |
Most of Novo Nordisk's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novo Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Novo Nordisk is extremely important. It helps to project a fair market value of Novo Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Novo Nordisk's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novo Nordisk's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novo Nordisk's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Novo Nordisk AS has 37.47 B in Cash And Equivalents. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is significantly lower than that of the firm.
Novo Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in cash and equivalents category among its peers.
Novo Nordisk Current Valuation Drivers
We derive many important indicators used in calculating different scores of Novo Nordisk from analyzing Novo Nordisk's financial statements. These drivers represent accounts that assess Novo Nordisk's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novo Nordisk's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 915.8B | 992.8B | 1.7T | 2.1T | 3.1T | 3.3T | |
| Enterprise Value | 904.8B | 990.4B | 1.7T | 2.1T | 3.2T | 3.3T |
Novo Nordisk ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novo Nordisk's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novo Nordisk's managers, analysts, and investors.Environmental | Governance | Social |
Novo Fundamentals
| Return On Equity | 0.89 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.47 % | ||||
| Current Valuation | 465.74 B | ||||
| Shares Outstanding | 3.37 B | ||||
| Shares Owned By Institutions | 10.17 % | ||||
| Number Of Shares Shorted | 6.05 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 27.60 X | ||||
| Price To Sales | 1.68 X | ||||
| Revenue | 232.26 B | ||||
| Gross Profit | 148.51 B | ||||
| EBITDA | 114.63 B | ||||
| Net Income | 83.68 B | ||||
| Cash And Equivalents | 37.47 B | ||||
| Cash Per Share | 16.57 X | ||||
| Total Debt | 27.01 B | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 0.92 X | ||||
| Book Value Per Share | 27.07 X | ||||
| Cash Flow From Operations | 108.91 B | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | 2.99 X | ||||
| Price To Earnings To Growth | 1.59 X | ||||
| Target Price | 941.31 | ||||
| Number Of Employees | 71.88 K | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 472.8 B | ||||
| Total Asset | 314.49 B | ||||
| Retained Earnings | 104.84 B | ||||
| Working Capital | (30.01 B) | ||||
| Current Asset | 8.03 B | ||||
| Current Liabilities | 5.95 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 2.05 % | ||||
| Net Asset | 314.49 B | ||||
| Last Dividend Paid | 9.9 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
Moving against Novo Stock
| 0.92 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.86 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.86 | GILD | Gilead Sciences | PairCorr |
| 0.68 | KZR | Kezar Life Sciences | PairCorr |
| 0.6 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Novo Nordisk Piotroski F Score and Novo Nordisk Altman Z Score analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.